This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Related article  • Similar articles in JAMA  Social Bookmarking   What's this?

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

In Reply: Dr Fukuda and colleagues question whether the effect of the BP intervention was greater for patients randomized to amlodipine than for patients assigned to ramipril or metoprolol. There was no significant relationship between the effect of the BP intervention and the antihypertensive drug group for the primary outcome of GFR slope or the main secondary clinical composite outcome comprising GFR events, end-stage renal disease, or death (P values for the BP by drug group interaction were .64, .61, and .18 for the chronic slope, total slope, and clinical composite outcomes, respectively). Thus, in accordance with the study design, our primary article addressed the overall BP comparison combining the 3 drug groups. Separate comparisons of the BP goals within the individual drug groups will be provided in subsequent publications.

In the amlodipine group alone, the mean (SE) chronic slope was 0.04 (0.64) mL/min per 1.73 m² per year . . . [Full Text of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

RELATED ARTICLE

Antihypertensive Drugs and Renal Protection
Michio Fukuda, Takeshi Usami, Atsuhiro Yoshida, and Genjiro Kimura
JAMA. 2003;289(9):1102-1103.
EXTRACT | FULL TEXT